Caris Life Sciences, Inc. is a biotechnology company specializing in advanced molecular science and precision medicine, with a primary focus on cancer diagnostics and treatment. Founded in 2008 and headquartered in Irving, Texas, Caris develops and delivers innovative solutions that leverage genomic, proteomic, and transcriptomic analysis to improve patient outcomes by personalizing therapy selection and disease management. The company is renowned for its pioneering role in precision oncology, having built one of the largest integrated multimodal databases of matched molecular and clinical outcomes data worldwide, encompassing over half a million patient records. Through its proprietary molecular profiling technologies and AI-driven platforms, Caris empowers physicians with detailed, actionable insights, informing critical decisions in early disease detection, treatment optimization, and the development of next-generation therapies. The company’s initiatives extend beyond cancer, aiming to revolutionize healthcare and improve the human condition across various complex diseases. Caris also leads collaborative research through its Precision Oncology Alliance, partnering with top cancer centers to accelerate biomarker-driven innovation in medicine.